(Q46916475)

English

A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer

scientific article published on 5 November 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17980406

A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17980406

phase II clinical trial

0 references

cervix uterine cancer

1 reference

based on heuristic

inferred from title

author name string

A Goncalves

1

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17980406

M Fabbro

2

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17980406

C Lhommé

3

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17980406

L Gladieff

4

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17980406

J-M Extra

5

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17980406

A Floquet

6

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17980406

L Chaigneau

7

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17980406

A Tisseron Carrasco

8

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17980406

P Viens

9

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17980406

language of work or name

0 references

publication date

5 November 2007

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17980406

Gynecologic Oncology

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17980406

108

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17980406

1

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17980406

42-46

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17980406

Cervical cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.07.057

7 January 2021

SOR guidelines for concomitant chemoradiotherapy for patients with uterine cervical cancers: evidence update bulletin 2004.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.07.057

7 January 2021

Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.07.057

7 January 2021

Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group stud

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.07.057

7 January 2021

Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.07.057

7 January 2021

Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.07.057

7 January 2021

Phase I trial of concomitant vinorelbine, cisplatin, and pelvic irradiation in cervical carcinoma and other advanced pelvic malignancies

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.07.057

7 January 2021

Phase II trial of vinorelbine in patients with advanced and/or recurrent cervical carcinoma: an EORTC Gynaecological Cancer Cooperative Group Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.07.057

7 January 2021

Phase II study of cisplatin and vinorelbine in squamous cell carcinoma of the cervix: a gynecologic oncology group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.07.057

7 January 2021

Evaluation of vinorelbine in persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.07.057

7 January 2021

Results of a European Organization for Research and Treatment of Cancer/Early Clinical Studies Group phase II trial of first-line irinotecan in patients with advanced or recurrent squamous cell carcinoma of the cervix

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.07.057

7 January 2021

Phase II study of topotecan and paclitaxel for recurrent, persistent, or metastatic cervical carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.07.057

7 January 2021

A phase II study of gemcitabine and cisplatin in patients with advanced, persistent, or recurrent squamous cell carcinoma of the cervix

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.07.057

7 January 2021

Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.07.057

7 January 2021

Human papilloma virus (HPV)-E6/E7 and epidermal growth factor receptor (EGF-R) protein levels in cervical cancer and cervical intraepithelial neoplasia (CIN).

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.07.057

7 January 2021

Epidermal growth factor increased the expression of alpha2beta1-integrin and modulated integrin-mediated signaling in human cervical adenocarcinoma cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.07.057

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.07.057

7 January 2021

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.07.057

7 January 2021

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.07.057

7 January 2021

Targeted inhibition of the epidermal growth factor receptor-tyrosine kinase by ZD1839 ('Iressa') induces cell-cycle arrest and inhibits proliferation in prostate cancer cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.07.057

7 January 2021

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.07.057

7 January 2021

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.07.057

7 January 2021

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.07.057

7 January 2021

Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.07.057

7 January 2021

ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.07.057

7 January 2021

Practical management of patients with non-small-cell lung cancer treated with gefitinib

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.07.057

7 January 2021

Dermatologic Side Effects Associated with Gefitinib Therapy: Clinical Experience and Management

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.07.057

7 January 2021

Identifiers

10.1016/J.YGYNO.2007.07.057

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17980406

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17980406

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46916475&oldid=2137689125"